Allogeneic hematopoietic stem cell transplantation in the elderly
- PMID: 17303434
- DOI: 10.1016/j.critrevonc.2007.01.004
Allogeneic hematopoietic stem cell transplantation in the elderly
Abstract
The development of reduced intensity or non-myeloablative conditioning (NST) in preparation for allogeneic stem cell transplantation (SCT) revolutionized the field and led to reconsideration of the dogma of upper age limit that was set up by the transplant centers as an eligibility parameter. Analysis of the literature data showed that NST regimens are associated with decreased transplant related mortality, and graft-versus-host disease, in comparison with standard myeloablative conditioning, in patients above the age of 50-55 years, or in younger patients with significant comorbidities. However we have to mention, that our considerations are based on the retrospective analysis of the literature data, and that well controlled prospective randomized studies are needed in order to definitely assess the role of NST. Comorbidity indices might be proved as the most important parameters for the choice of the most proper regimen for each patient in need and should be included in future trials.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Reduced-intensity conditioning regimens in malignant haematological diseases.Neth J Med. 2005 Feb;63(2):43-51. Neth J Med. 2005. PMID: 15766008 Review.
-
Update on non-myeloablative stem cell transplantation for hematologic malignancies.Int J Hematol. 2002 Aug;76 Suppl 1:368-75. Int J Hematol. 2002. PMID: 12430884 Review.
-
[Non-myeloablative allogeneic stem cell transplantation].Tidsskr Nor Laegeforen. 2007 Mar 15;127(6):721-4. Tidsskr Nor Laegeforen. 2007. PMID: 17363982 Norwegian.
-
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012. Biol Blood Marrow Transplant. 2009. PMID: 19135940
Cited by
-
Non-myeloablative allogeneic hematopoietic stem cell transplantation.Semin Oncol Nurs. 2009 May;25(2):120-8. doi: 10.1016/j.soncn.2009.03.006. Semin Oncol Nurs. 2009. PMID: 19411015 Free PMC article. Review.
-
Effect of rehabilitation in patients undergoing hematopoietic stem cell transplantation.Fukushima J Med Sci. 2023 Aug 10;69(2):73-83. doi: 10.5387/fms.2022-33. Epub 2023 May 11. Fukushima J Med Sci. 2023. PMID: 37164764 Free PMC article.
-
Allogeneic stem cell transplantation for refractory adult T-cell leukemia using a non-T-cell-depleted HLA-incompatible family donor graft, with reference to the grown-up child donor to parent recipient setting: report of a pilot study.Int J Hematol. 2008 Apr;87(3):319-26. doi: 10.1007/s12185-008-0042-2. Epub 2008 Feb 21. Int J Hematol. 2008. PMID: 18288565 Clinical Trial.
-
Post-transplant changes in physical functioning and quality of life in patients undergoing two allogeneic hematopoietic stem cell transplants.Int J Hematol. 2025 Jul 5. doi: 10.1007/s12185-025-04030-z. Online ahead of print. Int J Hematol. 2025. PMID: 40616729
-
Oral health-related quality of life of patients with oral chronic graft-versus-host disease.Support Care Cancer. 2021 Nov;29(11):6353-6360. doi: 10.1007/s00520-021-06197-7. Epub 2021 Apr 21. Support Care Cancer. 2021. PMID: 33884507 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources